Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

9d ago

CMMB

PremiumPress Releases

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

25d ago

CMMB

PremiumPress Releases

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

1M ago

CMMB

PremiumPress Releases

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

2M ago

CMMB

PremiumPre-Earnings

CMMB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

CMMB

PremiumPress Releases

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

9M ago

CMMB

PremiumPre-Earnings

Chemomab Therapeutics Ltd. (CMMB) Q4 Earnings Cheat Sheet

1y ago

CMMB

More CMMB News >

CMMB News on the Web

2024-04-18

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Yahoo Finance

Neutral

2024-04-02

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Yahoo Finance

Neutral

2024-03-25

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Yahoo Finance

Neutral

2024-03-07

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023

InvestorPlace

Neutral

2024-03-07

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Yahoo Finance

Neutral

2024-03-05

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Yahoo Finance

Neutral

2024-02-20

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Yahoo Finance

Neutral

2024-02-14

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Yahoo Finance

Neutral

News Score - Last 7 Days

Neutral

CMMB

Sector Average

Media Buzz

This Week1 articles

Weekly Average1 articles

News Sentiment

This Week50%

Sector Average58%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CMMB’s Media Buzz Sentiment?

1 articles about CMMB were published this week. In an average week, 1 articles are published.

What is CMMB’s weekly average amount of articles?

In an average week, 1 articles about CMMB are published.

What is CMMB’s News Sentiment?

50% of articles about CMMB were positive this week, compared to its sector average of 58%.

Healthcare Stocks that are Trending in the News

DAWNDay One Biopharmaceuticals

IMVTImmunovant

RVVRevive Therapeutics

NVSNovartis

ISRGIntuitive Surgical

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing